Drug Patents Expiring in 2033
1. List of Abilify Maintena Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
2. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver
Dosage: TABLET;ORAL
3. List of Aczone drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
| US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
| US11273132 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Sep 10, 2022 |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
4. List of Aklief drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(10 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 4, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM;TOPICAL
5. List of Alkindi Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675559 | ETON | Treatment of adrenal insufficiency |
Jan, 2033
(9 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
6. List of Antara (micronized) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(10 years from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia; Treating severe hypertriglyceridemia
Dosage: CAPSULE;ORAL
7. List of Aristada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
8. List of Arymo Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) | |
| US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
9. List of Austedo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
| M | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET;ORAL
10. List of Auvelity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8569328 | AXSOME | Compositions and methods comprising tilidine or related compounds and dextromethorphan |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
11. List of Baxdela drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 19, 2022 |
| New Indication (I) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
12. List of Belsomra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
Market Authorisation Date: 13 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
13. List of Bendeka drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(10 years from now) | |
| US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(10 years from now) | |
| US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia
Dosage: SOLUTION;IV (INFUSION)
14. List of Biktarvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9216996 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(10 years from now) | |
| US9732092 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
| New Patient Population (NPP) | Jun 18, 2022 |
| M | Feb 24, 2024 |
NCE-1 date: February, 2022
Market Authorisation Date: 07 February, 2018
Treatment: NA
Dosage: TABLET;ORAL
15. List of Bonjesta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526703 | DUCHESNAY | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
| US9375404 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
| US9937132 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
| US9089489 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(10 years from now) | |
Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 November, 2016
Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Dosage: TABLET, EXTENDED RELEASE;ORAL
16. List of Braftovi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
| New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy
Dosage: CAPSULE;ORAL
17. List of Byfavo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
18. List of Cabometyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
| New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
19. List of Carnexiv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
20. List of Cequa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(10 years from now) | |
| US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
| US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION;OPHTHALMIC
21. List of Clorotekal drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504666 | B BRAUN MEDICAL INC | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Dec, 2033
(10 years from now) | |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 September, 2017
Treatment: NA
Dosage: SOLUTION;INTRATHECAL
22. List of Complera drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(9 years from now) | |
Market Authorisation Date: 10 August, 2011
Treatment: NA
Dosage: TABLET;ORAL
23. List of Contrave drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
24. List of Cytalux drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(10 years from now) | |
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(10 years from now) | |
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(10 years from now) | |
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(10 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(10 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 29, 2026 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: November, 2025
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION;INTRAVENOUS
25. List of Daptomycin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357535 | HOSPIRA INC | Daptomycin formulations and uses thereof |
Sep, 2033
(10 years from now) | |
| US9655946 | HOSPIRA INC | Daptomycin formulations and uses thereof |
Sep, 2033
(10 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18
Dosage: POWDER;INTRAVENOUS
26. List of Descovy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2024 |
| New Indication (I) | Oct 3, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Market Authorisation Date: 04 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
27. List of Docetaxel drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(10 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution; Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; Treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; Use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; Treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; Use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; Treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; Treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy
Dosage: INJECTABLE;INJECTION
28. List of Empaveli drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(10 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
| Orphan Drug Exclusivity (ODE) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan so as to reduce the sensitivity of cells to complement-dependent damage
Dosage: SOLUTION;SUBCUTANEOUS
29. List of Entresto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 1, 2022 |
| M | Feb 16, 2024 |
| Pediatric Exclusivity (PED) | Apr 1, 2023 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure with preserved ejection fraction
Dosage: TABLET;ORAL
30. List of Epanova drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(9 years from now) | |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet; Treatment of hypertriglyceridemia
Dosage: CAPSULE;ORAL
31. List of Epclusa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8940718
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8921341
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8575135
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| New Strength (NS) | Mar 19, 2023 |
| M | Apr 27, 2025 |
| New Dosing Schedule (D) | Nov 15, 2022 |
| New Patient Population (NPP) | Mar 19, 2023 |
| Pediatric Exclusivity (PED) | May 15, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 28 June, 2016
Treatment: NA
Dosage: TABLET;ORAL
32. List of Erleada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 14, 2023 |
| New Indication (I) | Sep 17, 2022 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc)
Dosage: TABLET;ORAL
33. List of Esbriet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(10 years from now) | |
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 15 October, 2014
Treatment: Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder
Dosage: CAPSULE;ORAL
34. List of Esmolol Hydrochloride Double Strength In Plastic Container drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(10 years from now) | |
| US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(10 years from now) | |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
35. List of Evomela drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
36. List of Evrysdi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 7, 2027 |
| New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
| New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: NA
Dosage: FOR SOLUTION;ORAL
37. List of Eysuvis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10945948 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10940108 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US11219596 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10646436 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10993908 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10857096 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for delivering a composition to a mucus membrane; Administration to the eye of a patient for treatment of dry eye condition
Dosage: SUSPENSION/DROPS;OPHTHALMIC
38. List of Fetroja drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| New Indication (I) | Sep 25, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
39. List of Fintepla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603815 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9549909 | ZOGENIX INC | Method for the treatment of dravet syndrome |
May, 2033
(10 years from now) | |
| US9610260 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US9603814 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US10478441 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US10478442 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
|
US9610260
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9603815
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478441
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478442
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9603814
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US9549909
(Pediatric) | ZOGENIX INC | Method for the treatment of dravet syndrome |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 25, 2027 |
| New Product (NP) | Jun 25, 2023 |
| New Indication (I) | Mar 25, 2025 |
| Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION;ORAL
40. List of Genvoya drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US10039718
(Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(10 years from now) | |
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
41. List of Givlaari drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(10 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
May, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
42. List of Harvoni drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9393256
(Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Dosing Schedule (D) | Nov 15, 2022 |
| Orphan Drug Exclusivity (ODE) | Apr 7, 2024 |
| Pediatric Exclusivity (PED) | Oct 7, 2024 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 10 October, 2014
Treatment: NA
Dosage: TABLET;ORAL
43. List of Hetlioz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24-hour sleep-wake disorder; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists
Dosage: CAPSULE;ORAL
44. List of Hetlioz Lq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists
Dosage: SUSPENSION;ORAL
45. List of Ibsrela drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: NA
Dosage: TABLET;ORAL
46. List of Iclusig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 18, 2023 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; A method for treating chronic myeloid leukemia
Dosage: TABLET;ORAL
47. List of Idhifa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 1, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
48. List of Imbruvica drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
|
US10294232
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10752634
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9725455
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10106548
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10125140
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10961251
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294231
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9713617
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 25, 2022 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 2, 2024 |
| Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 13 November, 2013
Treatment: Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; Treatment of waldenstrom's macroglobulinemia
Dosage: CAPSULE;ORAL
49. List of Imvexxy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10471072 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US11065197 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US11123283 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US11116717 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US10888516 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US10568891 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US10668082 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US10258630 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
| US9180091 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(10 years from now) | |
| US10398708 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
50. List of Infugem drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241948 | SUN PHARM | Ready to be infused gemcetabine solution |
Jul, 2033
(10 years from now) | |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 July, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
51. List of Inveltys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10646437 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US11219597 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10864219 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating inflammation and/or other disorders in an eye of a patient
Dosage: SUSPENSION/DROPS;OPHTHALMIC
52. List of Ionsys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095706 | THE MEDICINES CO | Self-test for analgesic product |
Feb, 2033
(9 years from now) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL
53. List of Jentadueto Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 3, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
54. List of Kalydeco drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(10 years from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(10 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
| New Patient Population (NPP) | Apr 29, 2022 |
Drugs and Companies using IVACAFTOR ingredient
Market Authorisation Date: 17 March, 2015
Treatment: Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11147770; Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046
Dosage: GRANULE;ORAL
55. List of Kengreal drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(10 years from now) | |
Drugs and Companies using CANGRELOR ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method
Dosage: POWDER;INTRAVENOUS
56. List of Korlym drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500216 | CORCEPT THERAP | Optimizing mifepristone absorption |
Mar, 2033
(10 years from now) | |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
57. List of Kuvan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9216178
(Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(10 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: NA
Dosage: POWDER;ORAL
58. List of Kyprolis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ONYX THERAP | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
Market Authorisation Date: 20 July, 2012
Treatment: NA
Dosage: POWDER;INTRAVENOUS
59. List of Liletta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090186 | MEDICINES360 | Methods for using intrauterine systems and IUD insertion devices |
Oct, 2033
(10 years from now) | |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
60. List of Linzess drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(10 years from now) | |
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE;ORAL
61. List of Lokelma drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 18, 2023 |
| M | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
62. List of Lonhala Magnair Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604018 | SUNOVION RESP | Aerosol therapy device |
May, 2033
(10 years from now) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
63. List of Lorbrena drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
| Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
| New Indication (I) | Mar 3, 2024 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
64. List of Luzu drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(10 years from now) | |
| US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(10 years from now) | |
| US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(10 years from now) | |
Drugs and Companies using LULICONAZOLE ingredient
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM;TOPICAL
65. List of Lytgobi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 30, 2027 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET;ORAL
66. List of Mekinist drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
| M | Oct 6, 2022 |
| New Indication (I) | Jun 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection
Dosage: TABLET;ORAL
67. List of Mektovi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Method of treating melanoma; Treatment of melanoma with a braf mutation
Dosage: TABLET;ORAL
68. List of Mitigare drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675613 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US8927607 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9399036 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9555029 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
| US9789108 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(10 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Method of using colchicine for the prophylaxis of gout flares
Dosage: CAPSULE;ORAL
69. List of Naftin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
| US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
| US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
| US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
| US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
| US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL;TOPICAL
70. List of Natroba drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895388 | PARAPRO LLC | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Apr 28, 2024 |
Drugs and Companies using SPINOSAD ingredient
Market Authorisation Date: 18 January, 2011
Treatment: The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed
Dosage: SUSPENSION;TOPICAL
71. List of Noxafil drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 31, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2028 |
| New Indication (I) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
72. List of Nurtec Odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8759372 | BIOHAVEN IRELAND | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 27, 2025 |
| New Indication (I) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
73. List of Ocaliva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(10 years from now) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: TABLET;ORAL
74. List of Odefsey drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
Market Authorisation Date: 01 March, 2016
Treatment: NA
Dosage: TABLET;ORAL
75. List of Olumiant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | May 10, 2025 |
| New Chemical Entity Exclusivity (NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients with severe alopecia areata
Dosage: TABLET;ORAL
76. List of Omidria drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
| US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
| US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(10 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION;IRRIGATION
77. List of Onivyde drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492442 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(10 years from now) | |
| US11369597 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(10 years from now) | |
| US10980795 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(10 years from now) | |
| US9452162 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(10 years from now) | |
| US9339497 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(10 years from now) | |
| US9717724 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(10 years from now) | |
| US9364473 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 22, 2022 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
78. List of Onzetra Xsail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(10 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER;NASAL
79. List of Orfadin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9301932 | SWEDISH ORPHAN | Liquid pharmaceutical composition comprising nitisinone |
Feb, 2033
(10 years from now) | |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 22 April, 2016
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: SUSPENSION;ORAL
80. List of Oxbryta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
81. List of Ozempic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jan 16, 2023 |
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
| New Dosing Schedule (D) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof
Dosage: SOLUTION;SUBCUTANEOUS
82. List of Pemazyre drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement
Dosage: TABLET;ORAL
83. List of Phenylephrine Hydrochloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859623 | PARAGON BIOTECK | Methods and compositions of stable phenylephrine formulations |
Nov, 2033
(10 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 March, 2013
Treatment: Dilation of the pupil
Dosage: SOLUTION/DROPS;OPHTHALMIC
84. List of Phexxi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11439610 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337989 | EVOFEM INC | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
Mar, 2033
(10 years from now) | |
| US10568855 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 22, 2023 |
Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient
Market Authorisation Date: 22 May, 2020
Treatment: Prevention of pregnancy
Dosage: GEL;VAGINAL
85. List of Picato drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(10 years from now) | |
Drugs and Companies using INGENOL MEBUTATE ingredient
Market Authorisation Date: 23 January, 2012
Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL;TOPICAL
86. List of Plenvu drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10016504 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
| US9707297 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
| US8999313 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
| US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(10 years from now) | |
| US9326969 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
87. List of Prevymis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 8, 2024 |
| New Chemical Entity Exclusivity (NCE) | Nov 8, 2022 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
88. List of Prolensa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(10 years from now) | |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
89. List of Qbrexza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10548875 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10004717 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(10 years from now) | |
| US8859610 | JOURNEY | Crystalline glycopyrrolate tosylate |
Feb, 2033
(10 years from now) | |
| US9259414 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(10 years from now) | |
| US10543192 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(10 years from now) | |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH;TOPICAL
90. List of Qelbree drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(10 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(10 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 2, 2026 |
| New Patient Population (NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
91. List of Qudexy Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
92. List of Quillichew Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
| US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
93. List of Qulipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: NA
Dosage: TABLET;ORAL
94. List of Quviviq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
95. List of Relyvrio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2027 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL
96. List of Rezurock drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease
Dosage: TABLET;ORAL
97. List of Roszet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376470 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(10 years from now) | |
| US9763885 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(10 years from now) | |
Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 23 March, 2021
Treatment: Treatment of hyperlipidemia
Dosage: TABLET;ORAL
98. List of Rozlytrek drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 15, 2024 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer
Dosage: CAPSULE;ORAL
99. List of Rybelsus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 16, 2023 |
| New Product (NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: NA
Dosage: TABLET;ORAL
100. List of Scemblix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity (ODE) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
101. List of Secuado drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687474 | HISAMITSU | Patch |
Jul, 2033
(10 years from now) | |
| US10583121 | HISAMITSU | Patch |
Jul, 2033
(10 years from now) | |
| US10814002 | HISAMITSU | Patch and method for producing the same |
Jul, 2033
(10 years from now) | |
| US10022445 | HISAMITSU | Patch |
Jul, 2033
(10 years from now) | |
| US11123305 | HISAMITSU | Patch |
Jul, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 11, 2022 |
Drugs and Companies using ASENAPINE ingredient
Market Authorisation Date: 11 October, 2019
Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch
Dosage: SYSTEM;TRANSDERMAL
102. List of Sesquient drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUPIN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
103. List of Seysara drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 1, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt
Dosage: TABLET;ORAL
104. List of Soaanz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10154963 | SARFE PHARMS | Controlled-release formulations comprising Torsemide |
Oct, 2033
(10 years from now) | |
Drugs and Companies using TORSEMIDE ingredient
Market Authorisation Date: 14 June, 2021
Treatment: NA
Dosage: TABLET;ORAL
105. List of Sotyktu drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) | |
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 9, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy
Dosage: TABLET;ORAL
106. List of Spravato drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 5, 2024 |
| New Indication (I) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant
Dosage: SPRAY;NASAL
107. List of Stribild drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718
(Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(10 years from now) | |
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
108. List of Symdeko (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(10 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2023 |
| New Patient Population (NPP) | Jun 21, 2022 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 12 February, 2018
Treatment: Treatment of cystic fibrosis in patients 12 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->a, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s patent 10058546; Treatment of cystic fibrosis in patients 6 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s. patent 10058546; Treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Treatment of cf in patients 12 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, & 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive to tezacaftor/ivacaftor
Dosage: TABLET;ORAL
109. List of Symproic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET;ORAL
110. List of Tafinlar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
| M | Oct 6, 2022 |
| New Indication (I) | Jun 22, 2025 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection
Dosage: CAPSULE;ORAL
111. List of Tazverik drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 23, 2025 |
| New Indication (I) | Jun 18, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 23, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treating lymphoma; Method of treating sarcoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma
Dosage: TABLET;ORAL
112. List of Tibsovo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
| New Indication (I) | May 25, 2025 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myelogenous leukemia (aml); A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); A method of treating a cancer characterized by an idh1 mutation wherein the cancer is previously treated, locally advanced or metastatic cholangiocarcinoma
Dosage: TABLET;ORAL
113. List of Tigecycline drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(10 years from now) | |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
114. List of Tolsura drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9272046 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
| US10806792 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
| US8921374 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
| US10463740 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
| US9713642 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
115. List of Trikafta (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 8, 2024 |
| New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 21 October, 2019
Treatment: Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; And another composition comprising ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor
Dosage: TABLET;ORAL
116. List of Trudhesa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940278 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Jan, 2033
(9 years from now) | |
| US9919117 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
117. List of Tukysa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504370 | SEAGEN | NA |
Mar, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
118. List of Turalio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 2, 2024 |
| Orphan Drug Exclusivity (ODE) | Aug 2, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 02 August, 2019
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
119. List of Tybost drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718
(Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 22, 2026 |
| New Patient Population (NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
120. List of Ukoniq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 5, 2026 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy
Dosage: TABLET;ORAL
121. List of Ultravate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962028 | SUN PHARM INDUSTRIES | Topical steroid composition and method |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Aug 31, 2023 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2015
Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis
Dosage: LOTION;TOPICAL
122. List of Vascepa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
| US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
| US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
| US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(10 years from now) | |
| US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(10 years from now) | |
| US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
| US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(10 years from now) | |
| US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject | ||